BioLineRx Presents Preclinical Data from Triple Combination of BL-8040, Anti PD-1 and Chemotherapy Demonstrating Significant Reduction in Pancreatic T false

ביוליין אר אקס בע"מ	2 380
BIOLINE RX LTD
Corporation no: 513398750	9253

	Israel Securities Authority			Tel Aviv Stock Exchange		C002 ( Public )		Reported via MAGNA:	05/11/2019
	www.isa.gov.il			www.tase.co.il				Reference:	2019-02-108241	Time of broadcast: 14:50 14:40:19

Immediate Report

Regulation 4 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000

The corporation is a foreign private issuer as defined by U.S. Securities Laws.

Attached hereto is a report on

BioLineRx Presents Preclinical Data from Triple Combination of BL-8040, Anti PD-1 and Chemotherapy Demonstrating Significant Reduction in Pancreatic Tumor Growth and Favorable Changes in Tumor Microenvironment

6-K_BL-8040_051119_1_isa.pdf

References of previous documents relating to this matter(the reference does not constitute incorporation by reference):
Stock Exchange/Market: NASDAQ CM	Date of revision of form structure: 29/10/2019
Address: HaMa'ayan 2 , Modi'in 7177871   , Israel Tel: 08-6429100 , Fax: 08-6429101
E-mail address: info@BioLineRx.com   Company site: www.biolinerx.com
Previous names of reporting entity:
Name of the Signatory: Kotler Norman Harold Position of Signatory in the reporting corporation: General Counsel & Company Secretary Name of Employer Company:
Address: HaMa'ayan 2 , Modi'in 7177871 Telephone: 08-6429100 Facsimile: 08-6429101 E-mail: normank@biolinerx.com 1
Israel